Coluracetam (135463-81-9) Specifications
|Molecular Weight:||341.411 g/moll|
|Synonyms:||Coluracetam; BCI-540; MKC-231; BCI 540; MKC 231; BCI540; MKC231.|
|Solubility:||Soluble in DMSO|
|Storage Condition:||Dry, dark and at 0 – 4 C for short term (days to weeks) or -20 C for long term (months to years)|
|Application:||Raw Coluracetam powder (MKC-231) is a synthetic racetam drug purported to be a nootropic compound.|
|Appearance:||white crystalline powder|
Coluracetam (135463-81-9) NMR Spectrum
If you need COA, MSDS, HNMR for each batch of product and other information, please contact our marketing manager.
What is Coluracetam (135463-81-9)?
Raw Coluracetam powder (MKC-231) is a synthetic racetam drug purported to be a nootropic compound. It does not have a large body of evidence investigating it, but the mechanisms of action (as well as structute) appear to be very distinct from other racetam compounds like Piracetam or Aniracetam.
Raw Coluracetam powder appears to interact with a process known as high affinity choline uptake (HACU for short), which is the rate-limiting step of drawing choline into a neuron for synthesis into the neurotransmitter acetylcholine. Increasing the HACU rate appears to increase the activity of cholinergic neurons, so it is a desired target for cognitive enhancement.
Coluracetam (135463-81-9) benefits
- Improve Memory and Learning
- Improve Reading Comprehension and Free Recall
- Long-term Cognition Improvement
- Reduce Treatment-Resistant Depression
- Potential Neurogenesis promotion
- Can improve Mental Disability
- May Improve Vision
- Irritable Bowel Syndrome symptom improvement
- Coluracetam recreational use
Coluracetam (135463-81-9) uses
Coluracetam (INN) (code name BCI-540; formerly MKC-231) powder is a nootropic agent of the racetam family. It was initially developed and tested by the Mitsubishi Tanabe Pharma Corporation for Alzheimer’s disease. After the drug failed to reach endpoints in its clinical trials it was in-licensed by BrainCells Inc for investigations into major depressive disorder (MDD), which was preceded by being awarded a “Qualifying Therapeutic Discovery Program Grant” by the state of California.
Coluracetam (135463-81-9) Dosage
Most of the research on coluracetam was done on animals rather than humans, so there are no universally accepted dosing guidelines. The active dosage range is generally described as 5–20 mg. Users of coluracetam have reported a wide range of doses administered both orally and sublingually.
User feedback has also mentioned that tolerance to coluracetam powder can develop quickly. As with all medications, especially nootropics, it’s best to start at smaller doses and up the dose gradually as your body reacts and adjusts to the medication. Coluracetam is non-toxic and is considered to be well-tolerated and safe.
Coluracetam powder for sale(Where to Buy Coluracetam powder in bulk)
Our company enjoys long term relationships with our clients because we focus on customer service and providing great products. If you are interested in our product, we are flexible with the customization of orders to suit your specific need and our quick lead time on orders guarantees you’ll have great tasting our product on-time. We also focus on value-added services. We are available for service questions and information to support your business.
We are an professional Coluracetam powder supplier for several years, we supply products with competitive price, and our product is of the highest quality and undergoes strict, independent testing to ensure that it is safe for consumption around the world.
 Akaike A, et al. (1998). Protective effect of MKC-231, a novel high affinity choline uptake enhancer, on glutamate cytotoxicity in cultured cortical neurons. Jpn J Pharmacol.
 Bessho, T., Takashina, K., Tabata, R., Ohshima, C., Chaki, H., Yamabe, H., Egawa, M., Tobe, A., & Saito, K. (1996). Effect of the novel high affinity choline uptake enhancer 2-(2-oxopyrrolidin-1-yl)-N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b] quinolin-4-yl) acetoamide on deficits of water maze learning in rats. Arzneimittel-Forschung, 46(4), 369–373.
 Murai, S., Saito, H., Abe, E., Masuda, Y., Odashima, J., & Itoh, T. (1994). MKC-231, a choline uptake enhancer, ameliorates working memory deficits and decreased hippocampal acetylcholine induced by ethylcholine aziridinium ion in mice. Journal of Neural Transmission, 98(1), 1–13.doi:10.1007/bf01277590.
 Takashina K, Bessho T, Mori R, Eguchi J, Saito K. MKC-231, a choline uptake enhancer: (2) Effect on synthesis and release of acetylcholine in AF64A-treated rats. J Neural Transm (Vienna). 2008 Jul;115(7):1027-35. doi: 10.1007/s00702-008-0048-1. PubMed PMID: 18446264.
 Shirayama Y, Yamamoto A, Nishimura T, Katayama S, Kawahara R. Subsequent exposure to the choline uptake enhancer MKC-231 antagonizes phencyclidine-induced behavioral deficits and reduction in septal cholinergic neurons in rats. Eur Neuropsychopharmacol. 2007 Sep;17(9):616-26. PubMed PMID: 17467960.